<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05102617</url>
  </required_header>
  <id_info>
    <org_study_id>7051-PM01-2021</org_study_id>
    <nct_id>NCT05102617</nct_id>
  </id_info>
  <brief_title>Post Market Usability Evaluation Of The PicoSure Pro Device</brief_title>
  <official_title>Post Market Usability Evaluation Of The PicoSure Pro Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cynosure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The intended use of the PicoSure and PicoSure Pro devices used in this study is to treat&#xD;
      additional patients with the new PicoSure Pro device and collect additional data on the&#xD;
      devices.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are to be enrolled in this clinical study if they are a healthy male or female 18&#xD;
      years of age or older. Up to 100 subjects will be enrolled at up to 4 study centers. Subjects&#xD;
      will be enrolled into one of the 3 groups; Group A, Group B, or Group C.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Randomization is not used for determining which arm subjects will participate in, however, it will be used to determine which side of the treatment area will receive which treatment regimen (if in a group receiving split-face treatments).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Grading of Pre-Treatment vs. Follow Up Images</measure>
    <time_frame>30 day follow up</time_frame>
    <description>The investigator will grade the improvement they noticed between the baseline image and the follow up image based on the Global Aesthetic Improvement Scale (GAIS), which ranges from 1-5 as follows: Very Much Improved (1), Much Improved (2), Improved (3), No Change (4), Worse (5).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Wrinkle</condition>
  <condition>Acne Scars</condition>
  <condition>Benign Epidermal Pigmented Lesions</condition>
  <condition>Benign Dermal Pigmented Lesions</condition>
  <condition>Tattoo Removal</condition>
  <arm_group>
    <arm_group_label>Group A: Split-Face Device Only Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a split face treatment with the PicoSure Pro and/or PicoSure devices using different device settings on each half of the face.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Split-Face Treatment with Cosmeceuticals</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a full face treatment with the PicoSure Pro or PicoSure device and will use topical cosmeceuticals on only half of their face.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Device Only Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive treatments with the PicoSure Pro or PicoSure device on multiple areas of the body such as the face, décolletage, back, legs, arms, and hands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PicoSure Pro Device</intervention_name>
    <description>This device will be used for up to 4 treatments over the designated areas.</description>
    <arm_group_label>Group A: Split-Face Device Only Treatment</arm_group_label>
    <arm_group_label>Group B: Split-Face Treatment with Cosmeceuticals</arm_group_label>
    <arm_group_label>Group C: Device Only Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PicoSure Device</intervention_name>
    <description>This device will be used for up to 4 treatments over the designated areas.</description>
    <arm_group_label>Group A: Split-Face Device Only Treatment</arm_group_label>
    <arm_group_label>Group B: Split-Face Treatment with Cosmeceuticals</arm_group_label>
    <arm_group_label>Group C: Device Only Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Cosmeceuticals</intervention_name>
    <description>Topical cosmeceuticals, such as a hydrating serum or cream, will be applied on the designated area.</description>
    <arm_group_label>Group B: Split-Face Treatment with Cosmeceuticals</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A healthy male or female 18 years of age or older.&#xD;
&#xD;
          -  Willing to undergo treatments with the PicoSure and PicoPro devices for pigmentary&#xD;
             lesions, acne scars, skin revitalization, or tattoo removal.&#xD;
&#xD;
          -  Understands and accepts obligation not to receive any other procedures on the&#xD;
             treatment area through the length of the study.&#xD;
&#xD;
          -  Understands and accepts the obligation and is logistically able to be present for all&#xD;
             visits.&#xD;
&#xD;
          -  Is willing to comply with all requirements of the study and sign the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is female and pregnant, has been pregnant within the last 3 months, is currently&#xD;
             breast feeding or planning a pregnancy during the study period.&#xD;
&#xD;
          -  The subject is hypersensitive to light in the near infrared wavelength region.&#xD;
&#xD;
          -  The subject takes medication which is known to increase sensitivity to sunlight.&#xD;
&#xD;
          -  The subject has seizure disorders triggered by light.&#xD;
&#xD;
          -  The subject takes or has taken oral isotretinoin, such as Accutane®, within the last&#xD;
             six months.&#xD;
&#xD;
          -  The subject has an active localized or systemic infection, or an open wound in area&#xD;
             being treated.&#xD;
&#xD;
          -  The subject has a significant systemic illness, such as lupus, or an illness localized&#xD;
             in area being treated.&#xD;
&#xD;
          -  The subject has common acquired nevi that are predisposed to the development of&#xD;
             malignant melanoma.&#xD;
&#xD;
          -  The subject has herpes simplex in the area being treated.&#xD;
&#xD;
          -  The subject is receiving or has received gold therapy.&#xD;
&#xD;
          -  The subject is currently enrolled in an investigational drug or device trial, or has&#xD;
             received an investigational drug or been treated with an investigational device within&#xD;
             in the area to be treated 6 months to entering this study.&#xD;
&#xD;
          -  The subject has any condition or is in a situation which in the investigators opinion&#xD;
             may put the subject at significant risk, may confound study results or may interfere&#xD;
             significantly with the subject's participation.&#xD;
&#xD;
        Cautionary Criteria:&#xD;
&#xD;
          -  Has unprotected sun exposure within four weeks of treatment, including the use of&#xD;
             tanning beds or tanning products, such as creams, lotions and sprays may interfere&#xD;
             with the laser treatment; Investigator discretion is required to determine feasibility&#xD;
             of treatment administration.&#xD;
&#xD;
          -  Has a coagulation disorder or is currently using anti-coagulation medications.&#xD;
             Anticoagulants may cause excessive bleeding and interfere with posttreatment healing;&#xD;
             Investigator discretion is required to determine feasibility of treatment&#xD;
             administration for subjects taking anticoagulants.&#xD;
&#xD;
          -  Is taking medications that alter the wound-healing response which may interfere with&#xD;
             posttreatment healing and may require special precautions to be taken by a treating&#xD;
             Investigator.&#xD;
&#xD;
          -  Is known to have a history of healing problems or history of keloid formation,&#xD;
             Investigator discretion is required to determine the feasibility of treatment&#xD;
             administration.&#xD;
&#xD;
          -  Has a history of skin cancer or suspicious lesions, Investigator discretion is&#xD;
             required to determine feasibility of treatment administration.&#xD;
&#xD;
          -  Has had a chemical or mechanical epilation within the last six weeks may interfere&#xD;
             with the post treatment healing process; Investigator discretion is required to&#xD;
             determine feasibility of treatment administration.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Civiok</last_name>
    <role>Study Director</role>
    <affiliation>Director of Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sean Doherty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cynosure, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emil Tanghetti</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Dermatology and Laser Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jamie Trimper</last_name>
    <phone>(978) 256-4200</phone>
    <email>jamie.trimper@cynosure.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Dermatology and Laser Surgery</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emil Tanghetti</last_name>
      <email>et@dermatologyandlasersurgery.com</email>
    </contact>
    <investigator>
      <last_name>Emil Tanghetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cynosure, Inc.</name>
      <address>
        <city>Westford</city>
        <state>Massachusetts</state>
        <zip>01886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Doherty</last_name>
    </contact>
    <contact_backup>
      <email>info@seandohertymd.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sean Doherty</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

